Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
- Citation:
- Cancer Res vol 73 (24 Suppl) Abstract nr S5-01
- Meeting Instance:
- SABCS 2013
- Year:
- 2013
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2158
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- W. Sikov D. Berry C. Perou B. Singh C. Cirrincione H. Burstein C. Kuzma T. Pluard G. Somlo E. Port M. Golshan J. Bellon D. Collyar O. Hahn C. Hudis E. Winer
- Networks:
- Study
- CALGB-40603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: